The EMA at 20: The generic and biosimilar industries on taking a positive partnership forward
This article was originally published in Scrip
Executive Summary
The EMA is a key partner for the generic and biosimilar medicines industries, but two areas – duplicate applications under the centralised procedure and a global development framework for generic medicines – need attention, says the EGA's Adrian van den Hoven.
You may also be interested in...
The EMA at 20: The generic and biosimilar industries on taking a positive partnership forward
The EMA is a key partner for the generic and biosimilar medicines industries, but two areas – duplicate applications under the centralised procedure and a global development framework for generic medicines – need attention, says the EGA's Adrian van den Hoven.